Back to Journals » Drug Design, Development and Therapy » Volume 12

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

Total article views   HTML views PDF downloads Totals
17,572 Dovepress* 15,965+ 1,225 17,190
PubMed Central* 1,607 419 2,026
Totals 17,572 1,644 19,216
*Since 24 April 2018
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 1 1 2

View citations on PubMed Central and Google Scholar